⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TEVA News
Teva Pharmaceutical Industries Limited American Depositary Shares
Respiratory Inhaler Devices Market to Reach $51.9 billion, Globally, by 2034 at 4.8% CAGR: Allied Market Research
prnewswire.com
AZN
BIIB
TEVA
NVS
GSK
SUN
Rapid Growth in Transmucosal Systems Driven by High Bioavailability Benefits
globenewswire.com
AQST
TEVA
Teva Releases Q4 2025 Aide Memoire
globenewswire.com
TEVA
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
globenewswire.com
TEVA
Alcohol Use Disorder: Global Market Analysis, Trends and Competition Outlook 2025-2032 - Rising Adoption of AI-Driven Predictive Analytics in Mobile Health Apps - ResearchAndMarkets.com
businesswire.com
ALKS
TEVA
VTRS
Trends and Market Growth Opportunities in the Alcohol Use Disorder Industry, 2025-2032
globenewswire.com
ALKS
TEVA
VTRS
RDY
SUN
Medincell publie ses résultats financiers semestriels consolidés
businesswire.com
TEVA
Medincell Publishes its Consolidated Half-Year Financial Results
businesswire.com
TEVA
ABBV
Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application 1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
businesswire.com
TEVA
Le partenaire de Medincell, Teva Pharmaceuticals, annonce le dépôt auprès de la FDA américaine d’une demande d’autorisation de mise sur le marché 1 pour Olanzapine LAI (TEV‑’749 / mdc‑TJK) [...]
businesswire.com
TEVA